Summary of Findings Table ‐ AbobotulinumtoxinA 50U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
Summary of Findings Table ‐ AbobotulinumtoxinA 50U may leads to higher total adverse events compared with placebo (low certainty).
Summary of findings table ‐ NB‐UVB may leads to higher patient‐reported changes in symptoms compared with placebo (low certainty).
Summary of findings table ‐ NB‐UVB may leads to higher investigator Global Assessment (short‐term) compared with placebo (low certainty).
The review found no eligible studies for this question.
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).
The review found no eligible studies for this question.
Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
The review found no eligible studies for this question.
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
Oral miltefosine (50 mg for 28 days) probably leads to higher complete cure, at least 3 months after the end of treatment compared with placebo (same regimen) (moderate certainty).
Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).
Oral miltefosine (50 mg for 28 days) showed no clear difference in recurrence compared with placebo (same regimen) (low certainty).
Benzoyl peroxide may leads to higher participant's global self‐assessment of improvement (long‐term data) compared with placebo or no treatment (low certainty).